Anesiva's media center is designed to provide reporters with easy access to news about the company and its products for stories in development. If you don't find what you are looking for or need more information, please contact us.
| All Releases |
|---|
 |
Anesiva Completes Successful Meeting With FDA and Announces Plans to File New Drug Application for Pain Drug, 3268
Jul 12, 2006
|
13.5 KB
|
| |
SOUTH SAN FRANCISCO, Calif., July 12, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that, based on a successful pre-filing meeting with the U.S. Food and Drug Administration, the company will file a New Drug Application (NDA) in the September/October timeframe for its lead product candidate 3268...
|
|
|
Anesiva To Present At C.E. Unterberg, Towbin Emerging Growth Conference On July 12, 2006
Jul 6, 2006
|
9.2 KB
|
| |
SOUTH SAN FRANCISCO, CA, July 6, 2006 - Anesiva, Inc. (Nasdaq: ANSV) today announced that John P. McLaughlin, the company's chief executive officer, will present at the C.E. Unterberg, Towbin Emerging Growth Conference on July 12, 2006 at 2:50 p.m. EDT in New York City.
To access the live webcasts or the subsequent archived recordings...
|
|
|
Corgentech Changes Name To Anesiva To Reflect Focus On Robust Pipeline Of Pain Therapeutics
Jun 21, 2006
|
54.6 KB
|
| |
SOUTH SAN FRANCISCO, CA., June 21, 2006 -- Corgentech Inc. (Nasdaq: CGTK) today announced that it has changed its name effective immediately from Corgentech Inc. to Anesiva, Inc. (Nasdaq: ANSV) to reflect the company's robust, advancing pipeline of pain therapeutics. The name change was approved today by stockholders at the company's annual ...
|
|
|
Corgentech Secures $30 Million Committed Equity Financing Facility
Jun 20, 2006
|
53.4 KB
|
| |
SOUTH SAN FRANCISCO, Calif., June 20, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Corgentech Inc. (Nasdaq: CGTK) today announced that it has received a commitment for up to $30 million in common stock equity financing from Azimuth Opportunity Ltd. to support Corgentech's corporate and clinical development activities. Over the next two...
|
|
|
Corgentech Pain Drug, 4975, Demonstrates Statistically Significant Pain Reduction After Knee Replacement Surgeries
Jun 14, 2006
|
75.1 KB
|
| |
Corgentech Inc. (Nasdaq: CGTK) today reported positive, top-line clinical data from a Phase 2 clinical trial in total knee replacement surgeries showing that 4975, the company's novel, long-acting, non-opioid drug candidate being developed for site-specific, moderate-to-severe pain, demonstrated pain reduction at all pre-specified time intervals in...
|
|
|
Click here to download our most recent fact sheet.